CL King Initiates Coverage On Avanos Medical with Buy Rating, Announces Price Target of $31
Portfolio Pulse from richadhand@benzinga.com
CL King analyst Kristen Stewart initiates coverage on Avanos Medical (NYSE:AVNS) with a Buy rating and announces a price target of $31.
May 22, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avanos Medical (NYSE:AVNS) receives a Buy rating from CL King analyst Kristen Stewart, with a price target of $31.
The Buy rating and price target announcement by CL King analyst Kristen Stewart is a positive signal for Avanos Medical (NYSE:AVNS). This indicates that the analyst believes the stock has potential for growth and is likely to appreciate in value, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100